Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lessened by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC lessened its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 36.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 92,648 shares of the biopharmaceutical company's stock after selling 54,140 shares during the period. Orion Portfolio Solutions LLC's holdings in Amicus Therapeutics were worth $989,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Assenagon Asset Management S.A. acquired a new position in Amicus Therapeutics during the 2nd quarter worth approximately $8,386,000. AlphaCentric Advisors LLC lifted its position in shares of Amicus Therapeutics by 15.7% during the second quarter. AlphaCentric Advisors LLC now owns 202,500 shares of the biopharmaceutical company's stock worth $2,009,000 after purchasing an additional 27,500 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Amicus Therapeutics by 7.1% in the second quarter. Bank of New York Mellon Corp now owns 1,245,115 shares of the biopharmaceutical company's stock valued at $12,352,000 after purchasing an additional 82,065 shares during the period. Legato Capital Management LLC grew its holdings in Amicus Therapeutics by 864.0% during the 2nd quarter. Legato Capital Management LLC now owns 101,703 shares of the biopharmaceutical company's stock valued at $1,009,000 after purchasing an additional 91,153 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Amicus Therapeutics by 6.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 50,471 shares of the biopharmaceutical company's stock worth $501,000 after buying an additional 2,918 shares during the period.

Insider Activity

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the sale, the chief executive officer now owns 886,654 shares of the company's stock, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 30,401 shares of company stock valued at $339,363. Company insiders own 2.20% of the company's stock.

Amicus Therapeutics Stock Performance

FOLD stock traded up $0.54 during trading on Monday, hitting $9.90. 3,495,587 shares of the company's stock traded hands, compared to its average volume of 2,722,871. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of -29.12 and a beta of 0.60. Amicus Therapeutics, Inc. has a 52 week low of $9.02 and a 52 week high of $14.57. The stock has a fifty day moving average price of $10.51 and a two-hundred day moving average price of $10.62. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18.

Analyst Upgrades and Downgrades

FOLD has been the subject of a number of analyst reports. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They issued a "buy" rating and a $18.00 price objective for the company. Cantor Fitzgerald raised their price objective on Amicus Therapeutics from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Bank of America upped their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday, October 17th. StockNews.com raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Tuesday, December 10th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and issued a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Friday. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $16.88.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.